Product Code: GVR-2-68038-590-8
Primary Cell Culture Market Growth & Trends:
The global primary cell culture market size is expected to reach USD 11.59 billion by 2030, expanding at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for personalized and precision therapies has fueled the need for more accurate and relevant in vitro models. Primary cell culture provides a closer representation of human biology and physiology compared to traditional cell lines, making it an indispensable tool for studying disease mechanisms, drug discovery, and therapeutic development. Researchers and pharmaceutical companies are increasingly recognizing the importance of primary cell culture for improving the success rates of drug candidates, reducing costly late-stage failures, and ultimately delivering more effective and targeted treatments to patients.
Moreover, the field of regenerative medicine aims to replace or repair damaged tissues and organs, and primary cell culture plays a vital role in developing and engineering functional tissues. Primary cells are used to create tissue constructs, organoids, and bioengineered implants that closely mimic the structure and function of native tissues. These advancements have significant implications for regenerative medicine therapies, including tissue transplantation, wound healing, and the treatment of degenerative diseases. For instance, in April 2023, Mount Sinai launched a new institute for regenerative medicine to foster novel discoveries and explore new therapies for life-threatening diseases. The growing interest in regenerative medicine and the potential to revolutionize healthcare have led to increased investment and research in primary cell culture, propelling the market's growth.
The COVID-19 pandemic has significantly impacted the primary cell culture industry. While the pandemic disrupted various industries, including healthcare and research, it highlighted the crucial role of primary cell culture in understanding viruses and developing treatments. Primary cells have been instrumental in studying the mechanisms of SARS-CoV-2 infection, testing antiviral therapies, and evaluating vaccine efficacy. The pandemic has accelerated the demand for primary cell culture products and services as researchers worldwide focused on COVID-19-related studies.
Furthermore, several developments undertaken by key market participants, and increasing industry-academia collaborations are driving the global market. For instance, in January 2023, Bio-Trac and ATCC collaborated to conduct a training workshop to offer an overview of the principles of primary cell culture, organoids and spheroids, and other related cell culture techniques.
Primary Cell Culture Market Report Highlights:
- By product, the reagent and supplements segment dominated with a share of 37.7% in 2023, due availability of a wide range of high-quality reagents and supplements tailored for specific cell types and research applications
- By separation method, the enzymatic degradation segment dominated the market with a share of 32.15% in 2023, due to the advantages of this method such as less damage to cultures, a relatively short turnaround time, and a high output of sample representation
- By cell type, the animal cells segment dominated the market with a share of 59.41% in 2022. The high growth of the segment is attributed to the versatility, wide availability, and established research protocols for this cell type
- North America established a strong regional position in the global market with a 41.52% share in 2023 due to its highly developed healthcare infrastructure and favorable government policies
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Product Segment
- 1.1.1.2. Separation Method Segment
- 1.1.1.3. Cell Type Segment
- 1.1.1.4. Application segment
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Primary Sources
- 1.11. List of Abbreviations
Chapter 2. Primary Cell Culture Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Product and Separation Method Snapshots
- 2.3. Cell Type and Application Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. Primary Cell Culture Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Rising usage of primary cell culture products in in-vitro testing and drug screening
- 3.4.2. Increasing in demand for stem cell therapy and regenerative medicine
- 3.4.3. Rising incidence of cancer and other chronic diseases
- 3.4.4. Advancement in genetic engineering protocols
- 3.4.5. Rise in research funding for functional biology and research
- 3.5. Market Restraint Analysis
- 3.5.1. Ethical and regulatory concerns related to the use of primary cells
- 3.5.2. Finite Lifespan, slow growth and critical to handle
- 3.6. Primary Cell Culture Market Analysis Tools
- 3.6.1. Industry Analysis - Porter's
- 3.6.1.1. Supplier Power
- 3.6.1.2. Buyer Power
- 3.6.1.3. Substitution Threat
- 3.6.1.4. Threat of New Entrant
- 3.6.1.5. Competitive Rivalry
- 3.6.2. PESTLE Analysis
- 3.6.2.1. Political Landscape
- 3.6.2.2. Technological Landscape
- 3.6.2.3. Economic Landscape
Chapter 4. Primary Cell Culture: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Primary Cell Culture Market by Product Outlook
- 4.4. Market Size & Forecasts and Trend Analysis, 2018 - 2030 For The Following
- 4.4.1. Primary Cells
- 4.4.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.1. Fat Cells
- 4.4.1.1.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.2. Blood Cells
- 4.4.1.1.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.3. Nerve Cells
- 4.4.1.1.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.4. Bone Cells
- 4.4.1.1.4.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.5. Endothelial Cells
- 4.4.1.1.5.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.6. Skin Cells
- 4.4.1.1.6.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.7. Muscle Cells
- 4.4.1.1.7.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.1.1.8. Other Cells
- 4.4.1.1.8.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.2. Reagents and Supplements
- 4.4.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.2.1.1. Attachment Solutions
- 4.4.2.1.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.2.1.2. Buffers and Salts
- 4.4.2.1.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.2.1.3. Sera
- 4.4.2.1.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.2.1.4. Growth Factors and Cytokines
- 4.4.2.1.4.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.2.1.5. Others
- 4.4.2.1.5.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3. Media
- 4.4.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.1. Fat Cells Media
- 4.4.3.1.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.2. Blood Cells Media
- 4.4.3.1.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.3. Nerve Cells Media
- 4.4.3.1.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.4. Bone Cells Media
- 4.4.3.1.4.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.5. Endothelial Cells Media
- 4.4.3.1.5.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.6. Skin Cells Media
- 4.4.3.1.6.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.7. Muscle Cells Media
- 4.4.3.1.7.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.8. Stem Cells Media
- 4.4.3.1.8.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 4.4.3.1.9. Others
- 4.4.3.1.9.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
Chapter 5. Primary Cell Culture: Separation Method Estimates & Trend Analysis
- 5.1. Separation Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Primary Cell Culture Market by Separation Method Outlook
- 5.4. Market Size & Forecasts and Trend Analysis, 2018 - 2030 For The Following
- 5.4.1. Explant Method
- 5.4.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2. Enzymatic Degradation
- 5.4.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.1. Trypsin
- 5.4.2.1.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.2. Collagenase
- 5.4.2.1.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.3. Protease
- 5.4.2.1.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.4. Pronase
- 5.4.2.1.4.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.5. Dispane
- 5.4.2.1.5.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.6. Hyaluronidase
- 5.4.2.1.6.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.7. Neuraminidase
- 5.4.2.1.7.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.8. Elastase
- 5.4.2.1.8.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.9. DNase
- 5.4.2.1.9.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.10. Papain
- 5.4.2.1.10.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.11. Accutase
- 5.4.2.1.11.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.2.1.12. Others
- 5.4.2.1.12.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.3. Mechanical Separation
- 5.4.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 5.4.4. Others
- 5.4.4.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
Chapter 6. Primary Cell Culture: Cell Type Estimates & Trend Analysis
- 6.1. Cell Type Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Primary Cell Culture Market by Cell Type Outlook
- 6.4. Market Size & Forecasts and Trend Analysis, 2018 - 2030 For The Following
- 6.4.1. Animal Cells
- 6.4.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 6.4.2. Human Cells
- 6.4.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
Chapter 7. Primary Cell Culture: Application Estimates & Trend Analysis
- 7.1. Application Market Share, 2023 & 2030
- 7.2. Segment Dashboard
- 7.3. Global Primary Cell Culture Market by Application Area Outlook
- 7.4. Market Size & Forecasts and Trend Analysis, 2018 - 2030 For The Following
- 7.4.1. Cell & Gene Therapy Development
- 7.4.1.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 7.4.2. Vaccine Production
- 7.4.2.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 7.4.3. Model System
- 7.4.3.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 7.4.4. Virology
- 7.4.4.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 7.4.5. Prenatal Diagnosis
- 7.4.5.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 7.4.6. Others
- 7.4.6.1. Market Estimates and Forecasts 2018 - 2030 (USD Million)
Chapter 8. Regional Business Analysis
- 8.1. Regional Market Share Analysis, 2023 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Marker Size, & Forecasts Trend Analysis, 2018 - 2030:
- 8.5. North America
- 8.5.1. U.S.
- 8.5.1.1. Key Country Dynamics
- 8.5.1.2. Competitive Scenario
- 8.5.1.3. Regulatory Framework
- 8.5.1.4. U.S. Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.5.2. Canada
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Canada Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6. Europe
- 8.6.1. UK
- 8.6.1.1. Key Country Dynamics
- 8.6.1.2. Competitive Scenario
- 8.6.1.3. Regulatory Framework
- 8.6.1.4. UK Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.2. Germany
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Germany Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.3. Spain
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Spain Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.4. France
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. France Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.5. Italy
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Italy Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.6. Denmark
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Denmark Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.6.5.
- 8.6.7. Sweden
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Competitive Scenario
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Sweden Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.6.8. Norway
- 8.6.8.1. Key Country Dynamics
- 8.6.8.2. Competitive Scenario
- 8.6.8.3. Regulatory Framework
- 8.6.8.4. Norway Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.7. Asia Pacific
- 8.7.1. Japan
- 8.7.1.1. Key Country Dynamics
- 8.7.1.2. Competitive Scenario
- 8.7.1.3. Regulatory Framework
- 8.7.1.4. Japan Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.7.2. China
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. China Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.7.3. India
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. India Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.7.4. South Korea
- 8.7.4.1. Key Country Dynamics
- 8.7.4.2. Competitive Scenario
- 8.7.4.3. Regulatory Framework
- 8.7.4.4. South Korea Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.7.5. Thailand
- 8.7.5.1. Key Country Dynamics
- 8.7.5.2. Competitive Scenario
- 8.7.5.3. Regulatory Framework
- 8.7.5.4. Thailand Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.7.6. Australia
- 8.7.6.1. Key Country Dynamics
- 8.7.6.2. Competitive Scenario
- 8.7.6.3. Regulatory Framework
- 8.7.6.4. Australia Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.8. Latin America
- 8.8.1. Brazil
- 8.8.1.1. Key Country Dynamics
- 8.8.1.2. Competitive Scenario
- 8.8.1.3. Regulatory Framework
- 8.8.1.4. Brazil Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.8.2. Mexico
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Mexico Primary Cell Culture Market, 2018 - 2030 (USD Million)
- 8.8.3. Argentina
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Argentina Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.9. MEA
- 8.9.1. MEA Primary Cell Culture Market, 2018 - 2030 (USD Million)
- 8.9.2. South Africa
- 8.9.2.1. Key Country Dynamics
- 8.9.2.2. Competitive Scenario
- 8.9.2.3. Regulatory Framework
- 8.9.2.4. South Africa Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.9.3. Saudi Arabia
- 8.9.3.1. Key Country Dynamics
- 8.9.3.2. Competitive Scenario
- 8.9.3.3. Regulatory Framework
- 8.9.3.4. Saudi Arabia Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.9.4. UAE
- 8.9.4.1. Key Country Dynamics
- 8.9.4.2. Competitive Scenario
- 8.9.4.3. Regulatory Framework
- 8.9.4.4. UAE Market Estimates and Forecasts 2018 - 2030 (USD Million)
- 8.9.5. Kuwait
- 8.9.5.1. Key Country Dynamics
- 8.9.5.2. Competitive Scenario
- 8.9.5.3. Regulatory Framework
- 8.9.5.4. Kuwait Market Estimates and Forecasts 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company /Competition Categorization
- 9.3. Vendor Landscape
- 9.3.1. List of Key Distributors And Channel Partners
- 9.3.2. Key Customers
- 9.3.3. Key Company Market Share Analysis, 2023
- 9.3.4. Thermo Fisher Scientific, Inc.
- 9.3.4.1. Overview
- 9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.4.3. Product Benchmarking
- 9.3.4.4. Strategic Initiatives
- 9.3.5. Lonza
- 9.3.5.1. Overview
- 9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.5.3. Product Benchmarking
- 9.3.5.4. Strategic Initiatives
- 9.3.6. Merck
- 9.3.6.1. Overview
- 9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.6.3. Product Benchmarking
- 9.3.6.4. Strategic Initiatives
- 9.3.7. Corning Incorporated
- 9.3.7.1. Overview
- 9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.7.3. Product Benchmarking
- 9.3.7.4. Strategic Initiatives
- 9.3.8. Danaher
- 9.3.8.1. Overview
- 9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.8.3. Product Benchmarking
- 9.3.8.4. Strategic Initiatives
- 9.3.9. PromoCell GmbH
- 9.3.9.1. Overview
- 9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.9.3. Product Benchmarking
- 9.3.9.4. Strategic Initiatives
- 9.3.10. ATCC
- 9.3.10.1. Overview
- 9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.10.3. Product Benchmarking
- 9.3.10.4. Strategic Initiatives
- 9.3.11. FUJIFILM Irvine Scientific, Inc.
- 9.3.11.1. Overview
- 9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.11.3. Product Benchmarking
- 9.3.11.4. Strategic Initiatives
- 9.3.12. Mattek
- 9.3.12.1. Overview
- 9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.12.3. Product Benchmarking
- 9.3.12.4. Strategic Initiatives
- 9.3.13. Axol Bioscience Ltd.
- 9.3.13.1. Overview
- 9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.13.3. Product Benchmarking
- 9.3.13.4. Strategic Initiatives